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Current Understanding of KlippelTrenaunay Syndrome: A Review Article
Philip Sheridan

Abstract
Klippel-Trenaunay Syndrome (KTS) is a rare congenital disease that causes improper
lymph, capillary, and venous development that leads to malformations. The disease also
causes hypertrophy of soft and bony tissues that, along with lymphedema and the
previously stated malformations, causes localized enlargement. The most likely location
for this localized enlargement is in the lower extremities. The genetic mutations
associated KTS are within the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic
Subunit Alpha (PIK3CA) and Angiogenic Factor With G-Patch And FHA Domains 1
(AGGF1) genes. These mutations result in enhanced cell proliferation (angiogenesis).
Current treatments for KTS are focused on preventative measures (compression and laser
treatment). If those are not adequate, surgery is the next option involving removal of
vascular malformations and the associated excess tissue (including sclerotherapy,
debulking procedures, and last resort amputation). This review article evaluates current
developments in our understanding of the genetics, physiology, and anatomy of KTS in
order to investigate the development of better treatments for KTS.

Keywords: Klippel-Trenaunay Syndrome, hypertrophy, venous malformations,
PIK3CA gene, AGGF1 gene
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Introduction
Research on Klippel-Trenaunay Syndrome continues on a disease that has no cure. This
disease is characterized by the triad of capillary malformations, venous malformations,
and bony or soft tissue hypertrophy (Jacob et. al. 1998). Abnormal varicosities, that are
usually lateral, are common in KTS patients as well (Glovkzki & Driscoll 2007). The
venous malformations are centralized in the lower extremities in the vast majority of
patients (Cohen 2000). Hypertrophy of the affected areas is mainly determined by
lymphedema and venous-lymphatic malformations (Brandigi et. al. 2018). Lymphatic
stasis is the cause of edema in enlarged areas and can be treated primarily with
compression (Samuel & Spitz 1995).
In regard to the development of KTS, current research shows that the PIK3CA mutations
that cause malformations arise during embryogenesis (Luks et. al. 2015). Port wine stains
and hypertrophy of the effected limb is present as early as 38 weeks of age (Pereira et. al.
2017). KTS occurs sporadically with equal sex distribution across the sexes. However,
familial occurrences have been infrequently observed suggesting that the disease can be
inherited (Oduber et. al. 2008). Recent identification of potential genetic causes has
grouped KTS into the PIK3CA-related overgrowth spectrum or PROS (Keppler-Noreuil
et. al., 2015).

Materials and methods
The research was done for this scientific article via searches through scientific article
databases, such as Pubmed and Google scholar, to obtain sources dating from 1985 to
2018. The research was primarily done by searching the keywords ‘Klippel-Trinaunay
Syndrome’, ‘PIK3CA gene’, ‘AGGF1 gene’, ‘KTS treatment’, ‘mTOR’, and ‘Sirolimus’. All
the articles used were peer reviewed articles in the English language published in
academic journals.

Genetic Mutations associated with KTS
KTS is caused primarily by two genes, the PIK3CA and AGGF1 genes. The PIK3CA gene
encodes for the catalytic subunit Phosphatidylinositol-4,5-Bisphosphate 3-Kinase (PI3K),
made up of the p85α regulatory subunit and p110α catalytic subunit proteins This
signaling pathway is coupled to a tyrosine kinase receptor which is activated when its
ligand binds. In response to this activation, the PI3K converts phosphatidylinositol (4,5)–
bisphosphate (PIP2) to phosphatidylinositol (3–5) ‐triphosphate (PIP3). This conversion
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can be reversed by the tumor suppressor protein Phosphatase and tensin homolog
(PTEN). PIP3 then activates Protein Kinase B (AKT) by phosphorylation. The
phosphorylated AKT can then deactivate the tumor suppressor protein tuberous sclerosis
(TSC1/TSC2). Without the suppression of TSC1/TSC2, the mammalian target of
Rapamycin (mTOR) alters causing angiogenesis tissue overgrowth. However, mTOR can
be inhibited by Rapamycin (Figure 1).

Figure 1
PI3K-AKT pathway associated with overgrowth in KTS
In KTS patients, changes in the PIK3CA gene are involved with the angiogenesis and
tissue overgrowth. In particular, a missense mutation in PIK3CA at the p110α catalytic
subunit was observed in patients with KTS (Samuels & Waldman 2010). This leads to an
excessive activation of mTOR that affects vascular cell growth in KTS patients
(Vahidnezhad et. al. 2016).
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The AGGF1 gene also appears to be associated with the angiogenesis in KTS patients. In
this case, the mutation is at the 5q13.3 breakpoint (Tian et al. 2004). Variants in the AGGF1
gene are association with a susceptibility for KTS, specifically the two variant single
nucleotide polymorphisms rs13155212 and rs7704267 (Hu et al. 2008). The AGGF1 SNP
E133K has also been suggested to be associated with KTS due to the resulting change in
phosphorylation state of AGGF1 which results in venous malformations (Tian et al. 2004).
However, the association between the E133k variant of AGGF1 and KTS is weak due to
its presence in healthy controls. Thus, this polymorphism may be rather common rather
than specific to KTS (Barker et al. 2006). Overexpression of the AGGF1 gene increases
expression of venous gene markers flt4, dab2, and ephB4 and activated AKT (Chen et. al.
2012). Later studies confirm the finding that the AGGF1 gene can activate AKT,
suggesting that AKT activation is responsible for angiogenesis and vascular development
when mediated by AGGF1 (Zhang et al. 2016).
Alternatively, KTS may be caused by several gene mutations that have angiogenesis
functions and other growth regulations which may explain the variability from patient
to patient in phenotype and symptom expression (Oduber et. al. 2008). A translocation at
t(8;14)(q22.3;q13) has also been suggested as a possible genetic cause for the vascular and
tissue overgrowth (Wang et. al. 2001). KTS cases are sporadic yet there are some rare cases
in which autosomal dominant inheritance seems to be present suggesting the sporadic
mutations that cause KTS can be passed on (Ceballos‐Quintal et. al. 1996).

Treatment of KTS
Management of KTS continues to be primarily non-invasive, such as compression and
laser treatment, yet surgical treatment via excision of symptomatic varicose veins on KTS
patients that have patent deep veins resulted in significant clinical improvement of those
patients (Noel et. al. 2000). In 1991, invasive surgical treatment were rarely used and were
controversial (Gloviczki et. al. 1991). The best means of controlling KTS has been
compression (Baskerville et. al. 1985). This continues currently as the most common
method for conservative management of the disease (Glovkzki & Driscoll 2007) due to its
ability to reduce swelling via decreasing edema caused by lymphatic stasis (Samuel &
Spitz 1995).
Several new treatments and changes in management have been implemented in recent
years to treat the disease. The usage of a pulse-dye laser has been shown to treat KTS with
no reoccurrence when it was used within 2 weeks after birth (Rahimi et. al. 2017). Though
patients with KTS were often screened for Wilms tumor due to a perceived risk of
developing the cancer, no link between Wilms tumor and KTS has been found and thus
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this screening is unnecessary (Greene et. al. 2004). Sirolimus (Rapamycin) is being studied
for patients with vascular malformations due to its ability to inhibit mTOR (Schlögel et.
al. 2018), a pathway that functions to drive proper cell proliferation and growth via the
regulation of ribosomal biogenesis and protein translation (Tee & Blenis 2005). Studies
on several PROS patient cells via in vitro tests have shown that Sirolimus has a weak antiproliferative effect (Ranieri et. al. 2018).

Conclusion
Though the disease remains incurable, the developments in understanding and treatment
of KTS have made managing the disease much easier. Understanding of the genetics that
underlie KTS has greatly increased in the last few years and with this increase in
understanding has come available means of treating the disease, such as with the drug
Sirolimus, not previously known. Sirolimus seems to be the best drug option available
for treating KTS currently and further research into its full effects, both short and long
term, upon KTS patients will allow for the drug to be truly determined as a safe and
reliable drug option for the chronic disease. More research into other means of altering
the PIK3-AKT pathway and inhibiting the effects of the mutated AGGF1 and PIK3CA
genes will allow for other drug and treatment options of managing KTS to be available.
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